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Niches containing stem/progenitor cells are present in different anatomical locations along the human biliary tree and within liver
acini. The most primitive stem/progenitors, biliary tree stem/progenitor cells (BTSCs), reside within peribiliary glands located
throughout large extrahepatic and intrahepatic bile ducts. BTSCs are multipotent and can differentiate towards hepatic and
pancreatic cell fates. These niches’ matrix chemistry and other characteristics are undefined. Canals of Hering (bile ductules)
are found periportally and contain hepatic stem/progenitor cells (HpSCs), participating in the renewal of small intrahepatic bile
ducts and being precursors to hepatocytes and cholangiocytes. The niches also contain precursors to hepatic stellate cells and
endothelia, macrophages, and have a matrix chemistry rich in hyaluronans, minimally sulfated proteoglycans, fetal collagens, and
laminin. The microenvironment furnishes key signals driving HpSC activation and differentiation. Newly discovered third niches
are pericentral within hepatic acini, contain Axin2+ unipotent hepatocytic progenitors linked on their lateral borders to endothelia
forming the central vein, and contribute to normal turnover ofmature hepatocytes.Their relationship to the other stem/progenitors
is undefined. Stem/progenitor niches have important implications in regenerative medicine for the liver and biliary tree and in
pathogenic processes leading to diseases of these tissues.
1. Introduction
Thebiliary tree is a complex network of interconnected ducts,
which drain bile into the duodenum [1]. It can be divided
into intrahepatic and extrahepatic portions. The intrahepatic
biliary tree is composed of small (canals of Hering, bile
ductules, interlobular ducts, and septal ducts) and large (area
and segmental) bile ducts (BDs) [2, 3].
Cholangiocytes are specialized and heterogeneous epi-
thelial cells, lining BDs [4]. In particular, small cholangio-
cytes line small intrahepatic BDs, while large cholangiocytes
line large intrahepatic and extrahepatic BDs [4]. Interestingly,
small and large cholangiocytes differ on the basis of their
dimensions, ultrastructure (absence or presence of primary
cilia), functions, and proliferative capabilities [4–7]. In
addition, small and large ducts have a separate embryological
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Figure 1: Embryology of stem/progenitor cell niches within the biliary tree. (a) Human fetal livers (20th week gestational age).
Immunohistochemistry for cytokeratin (CK) 7. The ductal plate is present around portal tracts and contains CK7+ cells (arrows). Original
Magnification: 10x. (b) Human fetal hepatic duct at the liver hilum (20th week gestational age). Immunofluorescence for Sox9 and CK7.
Peribiliary glands (green arrows) derive from outpouches of the surface epithelium (red arrows) of the hepatic duct. Original Magnification:
20x.
origin. Ductal plates, found in fetal and neonatal livers, give
rise to small intrahepatic BDs, whereas the elongation and
molding of the hepatic diverticulum give rise to the large
intrahepatic and extrahepatic BDs (Figure 1) [2, 8].
In adults, there are multiple niches of stem/progenitor
cells residing in different locations along the human bil-
iary tree and niches found within the liver parenchyma.
Those within the biliary tree are found in peribiliary glands
(PBGs) and contain especially primitive stem cell popula-
tions, expressing endodermal transcription factors relevant
to both liver and pancreas, pluripotency genes, and even
markers indicating a genetic signature overlapping with that
of intestinal stem cells [9]. The biliary tree stem/progenitors
(BTSCs) support the renewal of large intrahepatic and extra-
hepatic BDs [1]. Canals of Hering (bile ductules), the smaller
branches of the biliary tree, are niches containing hepatic
stem/progenitors (HpSCs) and participating in the renewal
of the small intrahepatic BDs and in the regeneration of liver
parenchyma [10, 11]. A third set, found pericentrally within
the liver acinus, is newly discovered and is comprised of
Axin2+ unipotent hepatocytic progenitors that are linked on
their lateral borders to the endothelia forming the central
vein and constitute precursors to the mature hepatocytes in
normal liver turnover and mild regenerative responses [12].
2. Biliary Tree Stem/Progenitor Cells (BTSCs)
Beside HpSCs within the smaller branches of the biliary
tree, a second stem/progenitor cell niche is located along
large intrahepatic and extrahepatic BDs [13]. BTSCs represent
a stem/progenitor cell compartment located within PBGs
(Figure 2) [14]. PBGs are located in the lamina propria of
large intrahepatic and extrahepatic BDwalls and are commu-
nicating with the duct lumen [2, 15]. BTSCs are composed
of heterogeneous populations characterized by phenotypic
traits of ventral endoderm, expressing typical transcription
factors (SOX9, SOX17, and PDX1), surface (EpCAM, LGR5,
and/or CD133), and cytoplasmic markers (CK7, CK19) [1].
As a restricted population, a subset of the BTSCs (nearly
10%) expresses pluripotency markers such as OCT4, SOX2,
NANOG, SALL4, and KLF 4/5 and their in vitro capabilities
qualify them as primitive true stem cells [13]. BTSCs have
multipotent capabilities and can differentiate towards func-
tional hepatocytes, mature cholangiocytes, and pancreatic
endocrine cells [14]. Whether or not they can give rise to
acinar cells is yet to be determined.
The distribution of PBGs is not uniform, varying along
the biliary tree: PBGs are mostly found in the hepatopancre-
atic ampulla and are less numerous in common bile duct [13,
14]. PBGs are not present in gallbladder, but a BTSC-like com-
partment is located in the epithelial crypts [16]. Interestingly,
a proximal-to-distal axis in a maturational lineage is found
along the biliary tree [13, 17].The highest numbers of the very
primitive BTSCs, ones that are precursors to both pancreas
and liver, are located primarily within PBGs near the hep-
atopancreatic ampulla; with progression towards the liver
and intrahepatic BDs, there is a decline in the numbers of
these very primitive BTSCs and gradual increase in stem/
progenitors for cells with hepatic fates [13].
Furthermore, the PBG niches are characterized by the
presence of a radial axis in maturational lineages [13]: the
more undifferentiated and proliferating cells are located at
the bottom of the glands, near the fibromuscular layer at the
centers of the ducts; the cells with a committed phenotype are
found in the middle and the fully differentiated cells are in
continuum with the surface epithelium [13].
Recently, several lines of evidence in rodents and in
humans indicate that BTSCs and their niches are implicated
in the turnover of the surface epithelium of large intrahepatic
and extrahepatic BDs [18, 19]. An experimental mouse model
confirmed the existence within the PBGs of multiple cell
lineages and the proliferation of cells within PBGs after duct
injury [18]. Moreover, in human extrahepatic BDs affected by
cholangitis, proliferating progenitor cells weremainly located
in PBGs, which can be considered a local stem/progenitor cell
niche [19].
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Figure 2: Peribiliary glands (PBGs) are the niche of Biliary Tree StemCells (BTSCs). (a) PBGs are glands located within the lamina propria of
the extrahepatic and large intrahepatic bile ducts (yellow arrows). PBG distribution varies along the biliary tree, and PBGs are mostly found
in the hepatopancreatic ampulla (white stars) and in branching sites of the biliary tree. PBGs are not present in gallbladder, but a BTSC-
like compartment is located in the epithelial crypts (gray arrows). PBGs are composed of Sox9+ BTSCs. (b) Primary sclerosing cholangitis is
characterized by the inflammation of duct walls (red asterisks) and PBG hyperplasia (yellow arrows). PBGs are involved in biliary fibrosis and
are surrounded by 𝛼-smooth muscle actin (𝛼-SMA) fibrogenetic cells (white asterisks). Immunohistochemistry for Epithelial Cell Adhesion
Molecule (EpCAM) was counterstained with Periodic acid-Schiff (PAS). Immunofluorescence for cytokeratin (CK) 7, Sox9, and 𝛼-SMA are
included.
Accordingly, the ischemia-reperfusion injury of the
PBGs during liver transplantation procedures is associ-
ated with the loss of epithelial cells and the develop-
ment of non-anastomotic biliary strictures [20]. Further-
more, PBGs are activated in primary sclerosing cholangitis
(Figure 2(b)) and their hyperplasia has a key role in pro-
gression of biliary strictures [21]. Interestingly, proliferat-
ing BTSCs can produce Fas-Ligand and modulate inflam-
matory response by inducing “premature” T-cell apoptosis
[22].
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BTSC niches extend towards the pancreatic duct system
and pancreatic duct glands (PDGs) located along larger
pancreatic ducts. The PDGs represent the counterpart of
PBGs along the biliary tree [17] and contain a population of
committed pancreatic progenitor cells [17, 23]. The anatomi-
cal features shared by biliary tree and pancreatic duct system
are in touch with the similarities in pathologies affecting
these organs, thus suggesting a novel approach to the study
of biliary tract’s pathophysiology [24].
3. HpSCs Participate in the Regeneration of
Liver Parenchyma
Hepatoblasts (HBs) and their precursors, hepatic stem cells
(HpSCs), in humans and rodents, and rodent HpSC descen-
dants, called oval cells (Figure 3(a)), are capable of differ-
entiating to mature hepatocytes and cholangiocytes [25].
During embryological development, a ring of cells called the
ductal plate forms around the periportal mesenchyme at the
portal triads and consists of HpSCs (SOX9+, SOX17+ CK19+,
EpCAM+, NCAM+, and AFP−) and HBs (SOX9+, CK19+,
EpCAM+, ICAM-1+, and AFP+) [26]. Ductal plate cells have
stem cell properties (self-renewal and differentiative capabili-
ties) [27].The ductal plates transition to become the canals of
Hering in pediatric and adult liver and represent the HpSCs
niche [28]. Ductal plate cells give also rise to cholangiocytes
of interlobular BDs and to diploid hepatocytes [28]. Interest-
ingly, bile duct formations started with asymmetrical ductal
structures, partly lined by cholangiocytes and by HBs [29];
then, the HBs lining asymmetrical ducts differentiated to
cholangiocytes, with the formation of symmetrical ducts
lined only by cholangiocytes [29] and small numbers of HBs
tethered to or adjacent to the canals of Hering [27].
In pediatric and adult livers, the normal turnover is
accomplished by a combination of diploid adult hepatocytes
and cholangiocytes. Interestingly, Axin2+ hepatocytic pro-
genitors found pericentrally participate in the physiological
turnover of hepatocytes in mice in quiescence or following
minor injuries resulting in mild regenerative demands [12].
On the other side, a preexisting population of Sox9+ peripor-
tal hepatocytes (so-called hybrid hepatocytes) can undergo
extensive proliferation and replenish liver mass after chronic
injuries [30].Therefore, distinct subpopulation of adult hepa-
tocytes contribute to hepatic regeneration in both homeosta-
sis and injury [31]. In keeping, any participation/activation
of HpSCs or BTSCs is sufficiently minor as to be invisible
in analyses of homeostatic maintenance of liver parenchyma
[32].
Using an inducible Cre technology under the control
of the Sox9 transcriptional control elements, Furuyama et
al. found that Sox9-positive stem/progenitor cells indeed
participate in mouse liver homeostatic regeneration [33]. By
contrast, other authors using Cre technologies with other
genes and in all murine models found that experimental
injuries resulted in regenerative demands that cause the
stem/progenitors to give rise to only a few percent of
the adult parenchymal cells, ones always in the periportal
area [34–36]. In particular Espan˜ol-Sun˜er et al. [34] and
Rodrigo-Torres et al. [36] traced HpSCs in several experi-
mental models of liver injuries in mice using Osteopontin
(OPN) or hepatocyte nuclear factor (HNF)1𝛽, respectively.
Both manuscripts demonstrated that HpSCs contribute min-
imally to parenchymal turnover during choline-deficient,
ethionine-supplemented diet (CDE) while they do not con-
tribute at all in other models of liver injury such as 2/3 partial
hepatectomy, bile duct ligation (BDL), carbon tetrachloride
intoxication, and 3,5-diethoxycarbonyl-1,4-dihydrocollidine
diet (DDC). Moreover, the clonal analysis of Sox9+ cells
demonstrated that Sox9+ ductal progenitor cells give rise to
clonal oval cells but rarely produce hepatocytes in murine
models of liver injuries [37]. In keeping, parallel studies using
a hepatocyte fate-tracingmodel based on transthyretin (TTR)
gene demonstrated that mature (TTR+) hepatocytes are the
main cells responsible for replacing damaged hepatocytes in
experimental injuries [35, 38]. The results were confirmed
by genetic and nucleoside analog-based studies to mark and
track the origin and contribution of various cell populations
to liver regeneration [39]. Interestingly, mature hepatocytes
can undergo reversible ductal metaplasia in response to
injury and contribute to restoration of the hepatocyte mass
[40, 41].
We hypothesize that the remarkably high levels of poly-
ploidy in 3-4-week-old mice, levels of 95–97% or more, with
ploidy profiles from 4N to 32N in the liver plates, may restrict
the contributions by the BTSCs and HpSCs to the small
numbers of diploid cells, all of them located adjacent to the
biliary tree. In addition, there is a new report showing that
there are committed progenitor niches located pericentrally
and containing diploid, Axin2+ hepatocytic progenitors that
contribute to normal liver turnover by replacing senescing,
mature, polyploid hepatocytes [12]. The relationship of these
cells to those of BTSCs and HpSCs is yet to be defined.
This new study overcomes the past ones that suggested that
newly formed hepatocytes derived only from preexisting
hepatocytes [38–41]. Instead, it is now plausible that the inter-
pretations will be altered to give recognition to the Axin2+
unipotent hepatocytic progenitors. A similar reinterpretation
is likely for the prior report that hepatocytes can undergo
reversible ductal metaplasia, expand as ducts, and contribute
to the restoration of the hepatocyte mass in response to
injury [42]. Increasingly, the findings are coalescing and
reinforcing the prevailing concept that stem/progenitors are
the major sources of turnover in mild to extensive forms of
liver regeneration.
These past controversies were due in part to the potential
pitfalls in lineage tracing that include the choice of which
gene is used for lineage tracing, now shown to be critical in
defining the results [43], in the dominance inmurine livers of
highly polyploid hepatocytes [44], and in experimental injury
models (such as partial hepatectomy and choline-deficient,
ethionine supplemented diet), which do not determine a
complete blockade of hepatocyte replication [45, 46]. In this
latter regard, an elegant model in zebrafish demonstrated
that the extent of hepatocyte injury is fundamental to recruit
biliary cells participating in parenchymal recovery after
injuries; severe hepatocyte ablation is necessary to elicit the
extensive contribution of cells of biliary origin to hepatocyte
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Figure 3: Niche of hepatic stem/progenitor cells (HpSCs). (a) The cartoon shows the HpSC niche in adult liver. The HpSC niche is located
within the smaller branches of biliary tree at the interface between portal tract and hepatic parenchyma. The niche is composed of the stem
cells in combination with hepatic stellate cell precursors and Kupffer cells (resident macrophages). In the right side image, normal adult
human liver: immunofluorescence for Sox9 and cytokeratin (CK) 7 (Original Magnification: 20x); CK7+/Sox9+ HpSCs (arrows) are present
in canals of Hering and bile ductules. BD: bile duct; HA: hepatic artery; PV: portal vein. (b-c) Cartoons showing HpSC niche activation in
liver diseases. (b) The HpSC response is surrounded by a specialized niche, composed of precursors to hepatic stellate and to endothelial
cells and macrophages and of a matrix rich in laminin, hyaluronans, types III and IV collagens, and minimally sulfated proteoglycans. The
microenvironment of such a niche maintains the stem/progenitor/biliary phenotype and inhibits hepatocyte differentiation; the transition
of the niche matrix environment to one with minimal hyaluronans, less laminin, and an increase in more highly sulfated proteoglycans is
a necessary step to start the differentiation into a hepatocyte (or cholangiocyte) phenotype. Cells of mesenchymal origin and macrophages
can produce a variety of signals able to drive HpSC responses. Inflammatory macrophages can secrete TNF-like weak inducer of apoptosis
(TWEAK) sustaining the expansion of undifferentiated HpSCs; contrarily, tissue-repairing macrophages are able to activate canonical Wnt
pathway in HpSCs, triggering their differentiation towards hepatocytes. Activated hepatic stellate cells can secrete Jagged1, thus activating
Notch signaling inHpSCs, and also release type I collagen promoting biliary specification. (c)Cartoon showing the profibrogenic loop induced
by HpSC activation. HpSCs could activate the liver MF pool via Hedgehog (Hh) pathway, Osteopontin (OPN), and transforming growth
factor-𝛽1 (TGF-𝛽1), thus inducing collagen-I deposition.
mass restoration [42]. Recently, Lu and associates developed a
mousemodel in which the E3 ubiquitin ligaseMdm2 deletion
in hepatocytes causes apoptosis, necrosis, and senescence in
nearly all hepatocytes [43]. In this model, a florid HpSC
activation appeared and was necessary for survival and
complete functional liver reconstitution [43].
Complementing these findings are those by Kaneko et
al. in which the biliary tree was shown to possess unique
architectural and structural flexibilities and responses con-
tributing to maintaining liver homeostasis and in reactions
to injuries [44]. Thus, liver injuries determine dynamic
structural remodeling of the biliary tree, which corresponds
to the pattern of parenchymal cell damage [44]. Chronic
damage of pericentral hepatocytes triggers the expansion of
biliary branches from the periportal zone towards the injured
pericentral area [44]. Future studies are required to learn
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if biliary tree responses give rise to the Axin2+ hepatocytic
progenitors found pericentrally.
Functionally, HpSCs have been further investigated by
several in vitro assays, which have provided strong evidences
of stemness and differentiative potentiality [45]. In this
regard, HpSCs were isolated from fetal and adult human
livers on the basis of Epithelial Cell Adhesion Molecule
(EpCAM) expression [27, 46]. Moreover, HpSCs can be
distinctly separated from hepatoblasts by sorting for cells
coexpressing EpCAM and neural cell adhesion molecule
(NCAM), whereas, HBs are selectively isolated by coex-
pression for EpCAM and intercellular adhesion molecule
(ICAM) [26, 27]. More recently, a single Lgr5+ hepatic
stem cell expanded to form epithelial spheroids in vitro and
was able to differentiate into functional hepatocytes in vitro
and in vivo [47]. Organoids, floating aggregates of epithelia
and mesenchymal cells, containing Lgr5+ cells were able
to be expanded ex vivo and to give rise to hepatocytes
and cholangiocytes [48]. In parallel, long-term expansion ex
vivo of adult bile duct-derived stem/progenitors yielded cells
able to lineage restrict into hepatocytes, cholangiocytes, and
pancreatic islets [13, 14, 17]. Their potential for giving rise to
acinar cells is yet to be examined.
4. Role of HpSCs in Human
Liver Regeneration
If Axin2+ hepatocytic progenitor niches exist in humans,
whatever distinctions they have functionally with HpSC
niches in human livers remain to be clarified, and the HpSCs
have already been shown actively to contribute to liver
regeneration in human diseases [49]. This is due, in part, to
the fact that human liver diseases are characterized by a severe
and progressive impairment of hepatocyte or cholangiocyte
proliferation [50]. Proliferative capabilities of mature liver
parenchymal cells are limited and become exhausted due
to chronic damage and prolonged cell death [50]. This
is in accordance with the increase of proliferative cellular
senescence commonly described in hepatocytes [51] in end-
stage chronic liver pathologies. Moreover, specific insults
lead to the arrest of the hepatocyte cell cycle, such as iron
loading in hemochromatosis [52] or oxidative stress in non-
alcoholic fatty liver disease (NAFLD) [51, 53]. In parallel,
apoptosis of cholangiocytes [54], cellular senescence [55], and
a senescence-associated secretory phenotype [56] lead to the
production of proinflammatory cytokines and chemokines
that may modify the milieu of the bile duct and then trigger
fibroinflammatory responses in human cholangiopathies.
Consequently, the HpSC compartment is activated and cells
proliferate in all human liver diseases [50].
Under pathological conditions (Figures 3 and 4), unique
epithelial cell populations emerge and give rise to the so-
called ductular reaction (DR) [57]. DR represents a trans-
amplifying population consisting of strings of cells with
irregular lumina (reactive ductules) and a highly variable
phenotypical profile [58, 59]. Virtually all chronic liver dis-
eases (viral hepatitis, alcoholic/non-alcoholic steatohepatitis,
hemochromatosis, and primary biliary cirrhosis) and acute
(or acute-on-chronic) liver failure are characterized by the
emergence of DRs [50].
Variable phenotypes depend on the etiology and are cor-
related with the progression of the disease [50, 59]. In chronic
biliary diseases such as primary biliary cirrhosis (PBC) and
primary sclerosing cholangitis (PSC), DRs are prominent and
composed mostly of cells expressing biliary (Cytokeratins 7
and 19), neuroendocrine (NCAM, Chromogranin A), and
stem cell markers (Sox9, CD133) [50, 59]. On the other
hand, in liver diseases of nonbiliary origin, the cells within
reactive ductules show hepatocyte-like features (intermediate
hepatocytes) [50, 59]. Interestingly, in viral and alcoholic
cirrhosis, newly generated hepatocytes derive from DR and
represent the progeny of the HpSCs [60]. These newly
generated hepatocytes progressively lose biliary markers but
maintain EpCAM (stem/progenitor cell marker) expression
[60]. Moreover, the stem/progenitor pathway participates in
the formation of human cirrhotic nodules with the morpho-
logical sequence of bud maturation [61]. Progeny of the bud
sequencemay represent up to 70% of hepatocytes in cirrhotic
livers [61]. However, bud number is typically reduced in
biliary disease in association with duct loss and cholestatic
destruction of nascent buds [61].
The most prominent DRs can be encountered in acute
massive hepatocellular necrosis (fulminant hepatitis), where
DR cells are highly proliferating [59, 62]. In general, signs
of differentiation toward hepatocytes are minimal in acute
liver failure patients [63] and, when present, are a negative
prognostic factor [62]; this is due to the fact that, in acute liver
failure, activation of HpSCs is secondary to mature hepato-
cyte proliferation [63]. Moreover, in acute hepatitis, HpSCs
predominantly proliferate rather than differentiate [59], and
their differentiation starts not earlier than 1 week after the ini-
tial liver injury [63]. Interestingly, in acute-on-chronic liver
failure, HpSC activation and differentiation are more promi-
nent in comparison with acute liver failure and in decompen-
sated cirrhosis [63].
Finally, several lines of evidence have indicated thatHpSC
activation takes part in the regenerative response in alcoholic
liver disease [64, 65] and NAFLD [25]. Both in adult [51]
and pediatric [53, 66] patients with NAFLD, DR is prominent
in steatohepatitis but not in simple steatosis. DR appearance
and signs of differentiation are associatedwith hepatocyte cell
cycle arrest and apoptosis, and DR extension is correlated
with portal fibrosis [51, 53], inflammation [67], and clinical
parameters [68]. In alcoholic hepatitis (AH),HpSC activation
is correlated with a favorable clinical outcome [65]. In AH
patients, the extent of HpSC expansion is associated with
liver disease severity [65]. Interestingly, alcohol abstinence
induces a clinical improvement that positively correlates with
the expansion of the HpSC pool [65]. Unexpectedly, in the
natural course of AH, HpSCs do not differentiate into mature
hepatocytes due to signals coming from their niche [64].
Clarification of this is given below.
5. HpSC Activation Is Driven by
a Specialized Niche
In chronic liver injuries (Figures 3 and 4), the stem/pro-
genitor cell response is surrounded by a specialized niche
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Figure 4: Activation of hepatic stem/progenitor cell (HpSCs) niche in liver diseases. (a) Primary biliary cirrhosis. Immunofluorescence
for cytokeratin (CK) 7 and 𝛼-smooth muscle actin (𝛼-SMA); Original Magnification: 10x. The activation of HpSCs is characterized by the
appearance of ductular reactions (DR); DR consists of string of cells with irregular lumina (reactive ductules) composed of CK7+/Sox9+
HpSCs (yellow arrow). (b) Primary biliary cirrhosis; immunofluorescence for CK7 and 𝛼-SMA; Original Magnification: 10x. CK7+ DR is
surrounded by activated (fibrogenetic) hepatic stellate cells (red arrows).
[69]. This niche furnishes several key signals driving HpSC
activity (Figure 3(b)). In the hepatic stem cell niche [70],
HpSCs are found in association with angioblasts [27], with
precursors to hepatic stellate cells and endothelial cells [71,
72], andwithmacrophages [69, 70].The precursors have phe-
notypic traits overlapping with those of mature stellate cells
and endothelia but also are distinct. For examples, the stellate
cell precursorsminimally express retinoids, whereas these are
found in abundance in mature stellate cells; the endothelial
cell precursors do not express CD31 (PECAM) that is a
distinctive feature of mature endothelia. These precursors
release paracrine signals that are important for the mainte-
nance of the stem/progenitors in a quiescent state [72, 73].
These paracrine signals include matrix factors (hyaluronans,
types III and IV collagens) [71, 72], minimally sulfated
proteoglycans [74], and laminins [75] and soluble signals such
as leukemia inhibitory factor (LIF), hepatocyte growth factor
(HGF), stromal derived growth factor (SDGF), and epider-
mal growth factor (EGF) [71, 72]. Use of hyaluronan substrata
and a serum-free medium devoid of these soluble signaling
molecules enables self-replicative, clonogenic expansion of
human and rodentHpSCs [76].Therefore, the addition of any
of these factors to the conditions elicits differentiation of the
HpSCs to HBs and then their dramatic expansion [71, 72, 76].
In diseased tissue, there are activated hepatic stellate cells
and myofibroblasts (MFs) that produce distinct paracrine
signals (e.g., type I collagen, sulfated proteoglycans, and high
levels of the cytokines and growth factors) from those of
the quiescent stellate cells (e.g., network collagens, minimally
sulfated proteoglycans, and LIF) [71, 77].
The HpSCs, MFs, and macrophages produce a variety of
signals able to drive the HpSC response [78]. Interestingly,
macrophages can produce a variety of cytokines, which
have a key role in the prominent expansion of undiffer-
entiated HpSCs [79, 80]. Interestingly, a single injection of
unfractionated bone marrow cells in healthy mice is able to
induced HpSC proliferation and this is dependent by the
macrophage production of TNF-like weak inducer of apop-
tosis (TWEAK) [79]. Interestingly, TWEAK stimulatesHpSC
proliferation through its receptor Fn14 and HpSC expansion
was significantly reduced in Fn14-null mice or using a block-
ing anti-TWEAK antibody [80]. In chronic liver diseases,
macrophages are able to activate the canonical Wnt pathway
in HpSCs triggering their differentiation towards hepatocyte
[78]. In biliary diseases, activated stellate cells and MFs
can secrete Jagged1 that activates Notch signaling in nearby
HpSCs and, along with production of type I collagen, pro-
mote their biliary specification [59, 81].Therefore, Notch and
Wnt signaling pathways have a key role in HpSC proliferation
and specification [69].
A crucial element for the responses of theHpSCs andHBs
is represented by extracellular matrix (ECM) composition
[82]. Macrophages, MFs, HpSCs, and HBs have pivotal roles
in remodelling ECM through the production of a variety
of matrix metalloproteinases and their tissue inhibitors [69]
and in the synthesis of specific types of matrix components
[73]. The degradation of the collagen matrix by the met-
alloproteinases, coupled with the production of a laminin-
rich niche, leads to HpSC expansion; laminin maintains the
stem/progenitor/biliary phenotype and inhibits hepatocyte
differentiation [83]. By contrast, the loss of the laminin-rich
niche is a necessary step to start the differentiation into a hep-
atocyte phenotype [82, 83]. Interestingly, in alcoholic hepati-
tis, livers predominantly express laminin and, consequently,
HpSC expansion is inefficient at yielding mature hepatocytes
[64].
The interaction of HpSCs with a laminin-rich matrix is
promoted by 𝛽-galactoside-binding lectin galectin-3 (Gal-3)
[84]. Interestingly, Gal-3 is able to promote HpSC expansion
in an undifferentiated form [84]. Similarly, cell-cell and cell-
matrix interaction of unactivated HpSCs are mediated by
NCAM, a surface marker found on HpSCs and on both
angioblasts and endothelial cell precursors [27, 70, 73, 85].
Subsequent to liver injury, NCAM-positive cells expand
and typical NCAM posttranslational modification (polySia)
is produced [85]; PolySia weakens cell-cell and cell-matrix
interactions, facilitating HpSC migration away from the
laminin niche and their subsequent differentiation [85].
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In addition to signals passing from the niche to the stem/
progenitor cells, there are also signals from the stem/
progenitor cells to the niche (Figure 3(c)) [69]. HpSCs can
activate stellate/endothelial cells via theHedgehog (Hh) path-
way resulting in release of types of matrix components (e.g.,
type IV collagen, laminin, syndecans, and glypicans) asso-
ciated with normal liver regeneration [70, 73, 86]; other key
paracrine signals include OPN and transforming growth
factor-𝛽1 (TGF-𝛽1) which induce collagen-I deposition and
other matrix components associated with fibrosis by stellate
cells andMFs [87, 88].TheOPN synthesized by HpSCs could
also have an autocrine role inHpSC expansion andmigration
(via disruption of cell adhesion) [89]. In chronic pathological
conditions, this cellular cross-talk of paracrine signals could
be responsible in establishing a profibrogenic loop [57]; in
fibrogenesis, MF activation is secondary to the expansion of
the HpSC compartment mediated in part by the Hh pathway
[90] along with signaling pathways induced by chronic injury
[77].
In general, the emerging concept is that the expansion
of the HpSC niche (Figure 4(a)) represents an attempt to
participate in the regeneration of damaged liver. Unfortu-
nately, the persistent injury and the chronic inflammatory
milieu activate profibrogenetic pathways (Figure 4(b)) and
lead to deposition of type I collagen and associated matrix
components typical of scar formation and of fibrosis [57].
In addition, in several human diseases and experimental
settings, the expansion of the HpSC niche is strongly cor-
related with fibrosis progression [90]; the attenuation of the
liver stem/progenitor cell response in experimental settings
by the ablation of OPN expression [88] or by using anti-
TWEAK antibody [91] is able to prevent fibrogenic response
and improve liver regeneration. Interestingly, HpSCs are
hypothesized to contribute directly or indirectly to epithelial-
to-mesenchymal transitions (EMT), thus influencing the MF
pool [92]. The Hh pathway activation has a key role in EMT
of HpSCs and ductular cells in cirrhosis [93]. Interestingly,
EMT associated with HpSCs can also be driven by several
other factors such as the noncanonicalWnt pathway [94] and
TGF-𝛽1 [95].
6. Pathological Aspects and
Clinical Perspectives
From a point of view of pathology, distinct subpopulations of
mature hepatocytes and stem/progenitor cell compartments
are differently activated in the course of normal, quies-
cent liver biology versus different human pathologies. The
Axin2+ hepatocytic progenitors are activated for normal liver
turnover [12], and their role in human pathology should be
further investigated; the HpSC niche is activated in diseases
involving hepatocyte damage and ones involving interlobular
BDs following severe liver injurywhenmature cell senescence
develops [31, 69]; by contrast, the BTSC niche is involved in
diseases affecting larger intrahepatic and extrahepatic BDs
[21]. These aspects have been clearly elucidated comparing
stem/progenitor cells responses in different biliary patholo-
gies such as PBC and PSC [21]. PSC affects large intrahepatic
and extrahepatic BDs and, in addition, activation of PBGs is
triggered [21]. On the other hand, PBCprimarily affects inter-
lobular bile ducts and, therefore, PBG hyperplasia is almost
absent [21]. In summary, distinct stem/progenitor cell niches
are implicated in different forms of pathogenesis.This enables
one to analyze the natural course and complications of
different liver pathologies leading to a concept of a lineage-
specificity of liver diseases.
Investigations of stem/progenitor niches within the bil-
iary tree are acquiring particular relevance in relation to
primitive liver cancers (hepatocarcinoma: HCC), fibrolamel-
lar HCC, and cholangiocarcinoma (CCA). Indeed, recent
evidences indicate that a subgroup of HCC tumors, such as
cytokeratin-19 positive HCC and combined HCC-CCA, may
originate from HpSCs [96]. The HpSCs could represent the
cell of origin of a subtype of CCA such as cholangiolocar-
cinoma (CLC) and the so-called mixed-type CCA [97, 98].
On the other hand, PBGs and BTSCs could represent the
cell of origin of pure mucin-producing CCAs [99, 100]
and fibrolamellar-HCC [9]. In addition, clinical-pathological
correlates and risk factors for HCC and CCA support the role
of HpSC and BTSC in different subtypes of liver cancers [101].
The presence of stem/progenitor niches within the ducts
(intramural glands) and along the surface of ducts (extra-
mural glands) of the biliary tree has important implications
in the regenerative medicine for liver and biliary disorders
[102]. Actually, cell therapies for liver disease are demanding
given the organ shortage for orthotopic liver transplantation
[102, 103]. Mature hepatocyte transplantation is limited by
several issues, most importantly that the transplantation is
associated with complications such as emboli and that the
effects are transient [102, 103].Therefore, other cell types have
been proposed and tested in preclinical models or clinical
settings [102, 103]. In this context, HpSCs have been indicated
as candidate cells for clinical use [103]; HpSCs are long-
term expandable and highly stable at the chromosome and
structural level [48]; however, to date, few clinical trials have
been started or completed [102–104]. In a trial of 25 subjects
and 25 controls with decompensated liver cirrhosis due to
various causes, subjects received fetal liver-derived EpCAM+
cell infusions into the liver via the hepatic artery and
showed improvement inmultiple diagnostic and biochemical
parameters [105]. Beside decompensated liver cirrhosis, the
use of HpSCs in pediatric patients affected by inherited liver
inborn errors of metabolism has been tested [106, 107].
Alternatively, the transplantation of cells of mesenchymal
origin (such as macrophages, endothelial cells, or mesenchy-
mal stem cells) has been proposed as cell therapy approach
to liver cirrhosis to stimulate endogenous regeneration or
decrease fibrosis. The peripheral administration of autolo-
gous mesenchymal (or hematopoietic) stem cells has been
tested in several clinical trials in cirrhosis [102, 108, 109]; these
clinical studies of various autologous cells for liver disease
have been recently systematically reviewed and to date no
convincing benefit has been noted in adequately powered
randomized controlled studies [110].
Interestingly, human extrahepatic biliary tree represents
a suitable and large source for cell therapy [111]. Recently,
preliminary data regarding the infusion of BTSCs in patients
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with advanced cirrhosis have been reported, representing the
basis for forthcoming clinical trials [111].
In general, further studies focusing on the optimal routes
of cell transplantation, the need for immunosuppression, and
methods to improve the engraftment and proliferation rate of
transplanted cells are required [102, 103]. A key point regard-
ing the clinical use of cells with stem cell properties resides in
the potential risk of unwanted and unregulated cell growth;
taken in consideration that stem/progenitor cells can func-
tion as cell of origin for liver tumors, oncogenic risks should
be carefully considered when cells are candidate for therapy
in humans. To this regard, embryonic stem cells, induced
pluripotent stem cells, and induced hepatocyte cells may be
phenotypically and genetically unstable in vivo over a pro-
longed period and when transplanted into the damaged liver
[112]. Interestingly, extensive analysis of the genetic stability
of primary human HpSCs demonstrated that the expanded
cells preserve their genetic integrity over months in culture
[48]. Moreover, the long-term studies of BTSC in appropriate
animal models showed low oncogenetic risk [16]. In general,
oncogenic risks should be minimized by screening candidate
cells in long-term preclinical studies in animal models in
order to evaluate the safety and the absence of oncogenicity
of the cells.
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